Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Developing novel small molecule boosting agents for anti-cancer engineered T cell therapies
FY 2022-23
Summary
Immunotherapy is an emerging cancer therapy that uses a patient’s own immune cells to treat their cancer. Advancements in scientific technology now allow us to modify and train immune cells, such as T cells, to target and kill cancer cells. T cells provide the human body protection by surveilling and removing harmful cells from the body. A challenge within this treatment is that T cells require activation signals from their environment to survive, replicate, and kill cancer once they are delivered within the patient. Activation signals tend to be absent in a tumour environment, resulting in dysfunctional cells and less effective therapy. Some researchers approached this challenge by modifying the engineered T cells but observed toxic reactions. We may be able to address the current challenges by using a class of chemical compounds (“small molecules”) to provide the activation signals required for engineered T cell function. We identified Ferutinin, a plant-derived small molecule, as a promising drug candidate from an evaluation of 4000 compounds for their impact on engineered T cell function. We are interested in further investigating how Ferutinin and Ferutinin-like compounds enhance engineered T cell replication, survival, and tumour killing by combining T cell immunotherapy with Ferutinin in different tumour models. What we learn from this evaluation can help us to modify and improve the structure of Ferutinin to increase its engineered T cell boosting activity. We think investigating Ferutinin holds the promise of advancing cancer immunotherapies by introducing a novel drug that can improve engineered T cell killing, replication, and survival within the patient.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486498
Name
Adeel Zoya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing novel small molecule boosting agents for anti-cancer engineered T cell therapies
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Transfer; Cancer; Cancer Immunotherapy; Drug Discovery; Engineered T Cells; Ferutinin; High Throughput Screening; Immuno-Oncology; Structure Activity Relationship; T Cell Activation
Abstract
Immunotherapy is an emerging cancer therapy that uses a patient’s own immune cells to treat their cancer. Advancements in scientific technology now allow us to modify and train immune cells, such as T cells, to target and kill cancer cells. T cells provide the human body protection by surveilling and removing harmful cells from the body. A challenge within this treatment is that T cells require activation signals from their environment to survive, replicate, and kill cancer once they are delivered within the patient. Activation signals tend to be absent in a tumour environment, resulting in dysfunctional cells and less effective therapy. Some researchers approached this challenge by modifying the engineered T cells but observed toxic reactions. We may be able to address the current challenges by using a class of chemical compounds (“small molecules”) to provide the activation signals required for engineered T cell function. We identified Ferutinin, a plant-derived small molecule, as a promising drug candidate from an evaluation of 4000 compounds for their impact on engineered T cell function. We are interested in further investigating how Ferutinin and Ferutinin-like compounds enhance engineered T cell replication, survival, and tumour killing by combining T cell immunotherapy with Ferutinin in different tumour models. What we learn from this evaluation can help us to modify and improve the structure of Ferutinin to increase its engineered T cell boosting activity. We think investigating Ferutinin holds the promise of advancing cancer immunotherapies by introducing a novel drug that can improve engineered T cell killing, replication, and survival within the patient.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Adeel, Zoya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~